Admescope's 2019 in a nutshell - an excellent year!
9 January 2020
I could say that the last two weeks of December are in many ways the best weeks of the year. The busiest time of the year is just over, it is couple of days slowing down towards the well-earned holidays and the atmosphere is just great. Yet then after the Christmas it is the best days to have a holiday, as phone is not ringing and no urgent emails are dropping to the inbox.Read more
Preclinical formulations for pharmacokinetic studies
25 November 2019
When new drug compounds are synthetized, typically as solid powders, at the preclinical stage many properties of the compounds are not known. Apart from biological activity, for example particle size and crystal structure play important roles in further research for the compound. In many in vitro studies, the compound is just fully solubilized in solvent eliminating the issues described above.Read more
Responsible treatment of laboratory animals
17 October 2019
Admescope has always been committed to advance the ethical use of animals in science and to demonstrate its significance, in March 2019 we applied for an accreditation by AAALAC International. The accreditation stands for high quality animal care and use in research organisations, where the primary standards and legislation are followed.Read more
It's getting close to Midsummer
18 June 2019
The first half of 2019 is nearing its end and I can tell you that the time has truly flown by. The Sales and marketing team has been keeping busy flying and driving around Europe these past few months. We’ve visited seven different countries on roadshows, attended several conferences and as a result met a lot of new interesting people and old acquaintances.Read more
ADME – how to get started?
29 May 2019
During preclinical drug development, the number of compounds decreases from hundreds or thousands to the one entering the clinical trials. Understanding the ADME properties is essential to guide the decision makers and hence, ADME studies constitute an important part of preclinical drug development. When initiating this line of work for the first time, it may appear a bit puzzling. So, let’s have a simplified overview how get started with small molecules.Read more